Dive Brief: Merck & Co. disclosed Monday afternoon that it is pausing enrollment in two studies of its checkpoint inhibitor Keytruda (pembrolizumab) due to patient deaths. KEYNOTE-183 and KEYNOTE-185 will not recruit any further patients based on a recommendation from an external data monitoring committee. The two multiple myeloma studies are testing Keytruda in combination and Merck...
Tag: <span>KEYNOTE-183</span>
Post
3 Keytruda studies put on clinical hold after deaths
Dive Brief: The Food and Drug Administration has placed three combination trials of Merck’s flagship immunotherapy Keytruda (pembrolizumab) on clinical hold after a review of the studies found more deaths had occurred in the treatment arms. Merck had previously paused enrollment in two of the trials after initial reports of patient deaths. The three studies now on...